CNTA

NEUTRALM&A

Centessa Pharmaceuticals plc

2026-05-19

Price

$39.70

+0.15%

Score13.0Top Tier

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.6xvs 20d avg

Analysis

Centessa Pharmaceuticals (CNTA) is trading as a pure merger arbitrage vehicle following Eli Lilly's definitive agreement to acquire the company for $38.00 in cash plus a Contingent Value Right (CVR) of up to $9.00 per share. The stock's current price of $39.70 reflects the guaranteed cash floor plus approximately a 19% implied probability of the CVR milestones being met. Technical signals like QUIET_STORM perfectly align with the stock's microscopic 2.3% realized volatility as arbitrageurs lock in the spread. Furthermore, the broader RISK_ON macro regime and rock-bottom High Yield OAS (0.75%) eliminate any deal financing concerns, ensuring high institutional conviction in a Q3 2026 close.

Fired Signals

SURGEALPHA MALEQUIET STORMGOLDEN CROSSPERFECT STACKSELLER FATIGUE

Key Takeaways

Merger Arbitrage Pricing: At $39.70, the market is fully valuing the $38 base cash offer and pricing the $9 CVR at ~$1.70, capping near-term directional upside.
Signal Alignment: The QUIET_STORM signal and 0.6x relative volume reflect institutional deal absorption and a complete decoupling from broader market beta.
Clear Path to Close: With pristine macro credit conditions (0.75% HY OAS) and Lilly's deep pockets, deal financing risk is zero ahead of the June 12 shareholder vote.

← Back to 2026-05-19 View Full CNTA History →Yahoo Finance &nearr;